Table 5.
Frequency of solicited adverse events by time since vaccination in children and adults.
| 0–30 min | 31 min to 3 days | 4–14 days | |
|---|---|---|---|
| Children aged between 6–<18 years (n=194) | |||
| Arthralgia | 0 | 3 (3·5%) | 1 (9.1%) |
| Diarrhoea | 0 | 0 | 1 (9·1%) |
| Fatigue | 0 | 10 (11·6%) | 1 (9·1%) |
| Fever | 0 | 1 (1·2%) | 1 (9·1%) |
| Headache | 0 | 47 (54·7%) | 4 (36·4%) |
| Induration | 0 | 0 | 0 |
| Injection pain | 0 | 9 (10·5%) | 0 |
| Muscle pain | 0 | 4 (4·7%) | 1 (9·1%) |
| Myalgia | 0 | 4 (4·7%) | 1 (9·1%) |
| Vomiting | 0 | 1 (1·2%) | 0 |
| Other adverse events | 0 | 7 (8·1%) | 1 (9·1%) |
| Total | 0 | 86 (100·0%) | 11 (100·0%) |
| Adults aged 18 years and older (n=5643) | |||
| Arthralgia | 3 (2%) | 851 (13·5%) | 79 (12·3%) |
| Diarrhoea | 0 | 53 (0·8%) | 15 (2·3%) |
| Fatigue | 5 (3·3%) | 1233 (19·5%) | 112 (17·4%) |
| Fever | 2 (1·3%) | 8 (0·1%) | 2 (0·3%) |
| Headache | 41 (27·3%) | 1563 (24·7%) | 177 (27·5%) |
| Induration | 0 | 1 (<1%) | 0 |
| Injection pain | 70 (46·7%) | 362 (5·7%) | 8 (1·2%) |
| Muscle pain | 7 (4·7%) | 875 (13·8%) | 55 (8·5%) |
| Myalgia | 6 (4·0%) | 816 (12·9%) | 47 (7·3%) |
| Vomiting | 0 | 21 (0·3%) | 4 (0·6%) |
| Other adverse events | 16 (10·7%) | 537 (8·5%) | 145 (22·5%) |
| Total | 150 (100·0%) | 6320 (100·0%) | 644 (100·0%) |
Data are n (%); individuals might have had more than one adverse event.